Vepugratinib

N/A

Report date: 2025/10/21 20:00:06
NME

Base Information

Drug NameVepugratinib
Drug Alias NameLOXO-435LY3866288LY-3866288LOX-24350
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonists
TargetsFibroblast growth factor receptor 3
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisUrinary Bladder Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[21] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesSerán BioScience LLCEli Lilly And CompanyLilly Suzhou Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisUrinary Bladder Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A